Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BridgeBio Pharma, Inc. Director's Dealing 2025

May 20, 2025

30604_dirs_2025-05-20_c060d97c-1e3e-4dee-9d02-22692673a572.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-05-16

Reporting Person: Trimarchi Thomas (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-05-16 Common Stock F 21317 $33.84 Disposed 501988 Direct

Footnotes

F1: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 38,545 shares of Common Stock underlying the Reporting Person's Restricted Stock Units.